XanADu: A Phase II, Double-Blind, 12-Week, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of XanamemTM in Subjects With Mild Dementia Due to Alzheimer’s Disease (AD)
This XanADu Phase II study in mild Alzheimer’s Disease (AD) is to assess the safety, tolerability and efficacy of XanamemTM in subjects with mild dementia due to Alzheimer’s Disease. Subjects will be randomized to receive either 10mg once daily XanamemTM or Placebo at a 1:1 ratio in a double-blinded fashion.
This is a Phase II, randomised, multi-center, double-blind, placebo-controlled proof-of-concept study to assess the safety, tolerability and efficacy of oral XanamemTM once daily in adult subjects with mild dementia due to Alzheimer’s Disease.
Qualified participants for this study must be:
The overall study duration for an individual subject will be 17 to 20 weeks, including a screening period of one to 4 weeks, a double-blind treatment period of 12 weeks, and a follow-up period of 4 weeks. The total duration of the study is expected to be 2 years.
If you’d like to enroll to this clinical trial, complete the form below and we’ll get back to you:
For more information, please call Estela Soniel at (973) 398 2900. You can also send an email to firstname.lastname@example.org.
ClinicalTrials.gov Identifier: NCT02727699